Drug Type Small molecule drug |
Synonyms R 639, R-639, RO 67-0565 + [3] |
Target |
Mechanism ETA antagonists(Endothelin receptor type A antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H21N5O5S |
InChIKeyYBWLTKFZAOSWSM-UHFFFAOYSA-N |
CAS Registry290815-26-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 3 | US | 01 Jul 2005 | |
Diabetic Nephropathies | Phase 3 | US | Spera Pharma, Inc.Startup | 01 Jul 2005 |
Diabetic Nephropathies | Phase 3 | US | 01 Jul 2005 | |
Kidney Failure, Chronic | Phase 3 | US | 01 Jul 2005 | |
Glaucoma | Discovery | CH | 04 May 2009 |
Not Applicable | 761 | zexcidtqui(snqeqgafoj) = an excess of congestive heart failure (CHF) events occurred in the avosentan treatment arms which was likely due to increased sodium/fluid retention and led to premature termination of the trial lgyrzagcqk (tkdtskxaag ) | Negative | 30 Oct 2012 | |||
Not Applicable | - | 8 | rkwkphkcuh(omzjglhvlf) = a closed eye after dosing appeared in 1 of 8 eyes with the highest concentration of 0.3% rnsvxkvknd (mqcejmkeue ) View more | Positive | 01 Apr 2009 | ||